ABSTRACT OF THE DISCLOSURE

Method of treating conditions associated with raised activity of core 2 GlcNAc-T by administering an inhibitor of UDP-GlcNAc:Galβ1,3GalNAc-R (GlcNAc to GalNAc) β1,6-N- acetylglucosaminyl transferase (core 2 β1,6 N-acetylaminotransferase, core 2 GlcNAc-T -EC 2.4.1.102). Diseases associated with raised activity of core 2 GlcNAc-T include inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers, including treatment or prevention of metastasis, or diabetic retinopathy.